Blog
RSS FeedPosted by Michael Wonder on 20 Jun 2019
Sustainable discovery and development of antibiotics — is a non-profit approach the future?
19 June 2019 - Shifting to a nonprofit-driven model for development of antibiotics could encourage discovery and development of truly needed ...
Posted by Michael Wonder on 20 Jun 2019
Drug prices and innovation
20 June 2019 - The crisis in drug pricing has reached global proportions. ...
Posted by Michael Wonder on 27 Feb 2019
Economic analysis falls short when it comes to medicines’ value
26 February 2019 - For the past two decades, a plethora of organisations identified by various innocuous acronyms (e.g., NICE) ...
Posted by Michael Wonder on 20 Feb 2019
New drug landscape dominated by high cost medicines
19 February 2019 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, ...
Posted by Michael Wonder on 14 Feb 2019
Quebec appeals court orders province to restore full coverage of rheumatoid-arthritis drug Remicade
13 February 2019 - Quebec’s highest court has ordered the provincial government to restore full public coverage of Remicade, an ...
Posted by Michael Wonder on 06 Feb 2019
FDA finalises new policy to encourage widespread innovation and development of new buprenorphine treatments for opioid use disorder
6 February 2019 - Today, the U.S. FDA issued a final guidance, “Opioid Use Disorder: Developing Buprenorphine Depot Products for Treatment,” ...
Posted by Michael Wonder on 24 Jan 2019
Ottawa’s push for lower drug costs may hurt patients, stunt innovation
24 January 2019 - The federal government’s plan to lower prescription drug prices could impede access and thus limit the ...
Posted by Michael Wonder on 24 Jan 2019
Toward an effective innovation agenda
23 January 2019 - Digital technologies have transformed the U.S. and global economies, offering tremendous benefits to consumers and financial success ...
Posted by Michael Wonder on 21 Jan 2019
New agreement on branded drugs for the NHS
18 January 2019 - The new Voluntary Scheme for Branded Medicines Pricing and Access began on 1 January and was ...
Posted by Michael Wonder on 15 Jan 2019
Would drug price controls kill innovation?
14 January 2019 - Affordability doesn’t need to come at the expense of innovation. ...
Posted by Michael Wonder on 11 Jan 2019
Regeneron CEO: ‘we need a carrot-and-stick system’ to balance pricing and innovation
10 January 2019 - Amid ongoing furore over prescription drug pricing, Regeneron Pharmaceuticals chief executive Len Schleifer has sometimes gleefully ...
Posted by Michael Wonder on 07 Jan 2019
2018: a year of innovation, efficiency, and new advances in drug therapy for the American public
7 January 2019 - The beginning of a new year is a good opportunity to look back over the past ...
Posted by Michael Wonder on 18 Dec 2018
Statement from FDA Commissioner and Director of the Center for Devices and Radiological Health on new steps to promote innovations in medical devices that help advance patient safety
18 December 2018 - Spurring innovation of medical products so that patients can have access to safe, effective treatments that ...
Posted by Michael Wonder on 12 Dec 2018
Bernie Sanders' drug price controls would stifle medical innovation
11 December 2018 - Senator Bernie Sanders and Representative Ro Khanna recently proposed bills that would impose price controls on ...
Posted by Michael Wonder on 07 Dec 2018
Underuse of innovative medicines in Germany: A justification for government intervention?
6 December 2018 - The German market for innovative medicines is characterised by simultaneous underuse and overuse. ...